tbuckley/cabot-search huggingface dataset:
AB0657 Small intestinal bacterial overgrowth in relation to gastrointestinal symptoms in systemic sclerosis
Authors: MDP Cruz-Dominguez, G Garcia-Collinot, EO Madrigal-Santillan, A Carranza-Muleiro, LJ Jara, DH Montes-Cortes, G Medina-Garcia, O Vera-Lastra
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Autonomic dysfunction, smooth muscle fibrosis and vascular damage lead to small intestinal bacterial overgrowth (SIBO) in Systemic Sclerosis (SSc). SIBO is characterized by diarrhea, abdominal pain, bloating, malabsorption and malnutrition. <h3>Objectives</h3> To evaluate by NIH PROMIS® gastrointestinal symptoms scales and SIBO by hydrogen breath test (HBT) in patients with SSc. <h3>Methods</h3> We include 68 patients with SSc (ACR-EULAR 2015) who signed informed consent. NIH PROMIS®questionarie was applied to evaluated gastrointestinal symptoms and classified in not symptomatic, least, mildy, moderately and most symptomatic. Glucose HBT was applied after 14 hours fast, oral hygiene and 30 days free of antibiotics. Patients who has a negative HBT with symptoms associated to glucose ingestion we repeat test with lactulose. <h3>Results</h3> We applied questionnaire to 58 SSc patients, age 52 (26–75)years, 65 (96%) female and 3 (4%) males, disease duration 13 (1–40) years, limited SSc 41 (59%) and diffuse 27 (41%), body mass index 24 (12–39). They are using prednisone (28%), micofenolate (14%), methotrexate (19%), azatioprin (5%), amlodipine or nifedipine (33%). Patients had continuous and very high increase of parts per millon (ppm) of exhaled Hydrogen: min0: 13 ppm (5–21), min15:17 ppm (5–43), min30:17 (3–49), min45:18ppm (7–103), min 60:22ppm (8–145), min90:18ppm (2–250), min120:25ppm (3–212), min150:71ppm (3–235). Normal values: &lt;10 ppm during total test (Figure1). Frequency of gastrointestinal symptoms were flatulence (87.5vs81.2%), nausea/vomiting (72.7vs37.6%), constipation (65.6vs40%), diarrhea (45.2vs33.4%), abdominal pain %) and incontinence (39.4vs31.3%) respectively between SCB (+) positive and negative. Hyperproduction of hydrogen in breath had a direct correlation to severity of their symptoms (p≤0.05). The severity of diarrhea was in close relation to the severity of its rectal incontinence (r=0.73,p=0.001), and greater abdominal pain with flatulence (r=72, p=0.001). <h3>Conclusions</h3> Gastrointestinal symptoms are common in SSc regardless of whether they have SIBO. However, a higher Row Score SGI or moderate severe status (NIH PROMIS) correlates with high H scores from the 30th minute, therefore, the questionnaire is useful within the SSc assessment. <h3>Disclosure of Interest</h3> None declared
AB0606 Mortality associated factors to idiopathic inflammatory myopathies (IIMS)
Authors: AC Costi, P Sansinanea, C Pena, A Testi, A Salas, J Marcos, V Arturi, A Vulcano, M Pera, R García Salinas, R Aguila Maldonado, L García Var, V Nagua, MA García
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Idiopathic inflammatory myopathies (IIMs) include a group of muscular diseases characterized by the presence of muscle inflammation. The mortality of the IIMs has been estimated between 13 and 50%. <h3>Objectives</h3> To evaluate mortality rate and associated factors in patients with IIMs. <h3>Methods</h3> Retrospective, observational study, where patients with IIMs (Bohan &amp; Peter 1975) were included. Data were obtained from medical records from patients with myopathy (Increase CK, muscle weakness, cutaneous involvement, interstitial lung involvement) evaluated in a reference rheumatology center of Argentina (1992–2016). Descriptive statistics were performed. Chi2 test, Student9s test or Mann Whitney as appropriate multivariate logistic regression analysis. <h3>Results</h3> From 102 patients evaluated 89 enter the study, 73% were female. Mean age at diagnosis 48±14 years. Clinical Manifestations: Skin involvement 77% (erythema Heliotrope 51%, rash on the neck and V-sign 60%, back and shoulders 50%, photosensitivity 60%, Gottron9s papules 50%, pruritus 33%, erythema peri nail 21%), pulmonary involvement 19% Raynaud 28%, muscle weakness 86%, muscle weakness of the neck 33%, respiratory muscles 13%, myalgias 60% and dysphagia 53%. Muscle biopsy: performed in 36/89 with pathological findings in 83%, electromyogram performed in 35%. Intensive care unit admission 14/89 (16%). Laboratory: raised CPK 68% with an mean value 3527 IU/ml, raised Transaminase 60%, ANA positive 65%, SSA/RO 25%, Jo1 4.4%, RNP 7%, increased CRP 28% and ERA 59%. Clinical Subtypes IIMs: Dermatomyositis (DM): 61%, Antisynthetic syndrome (AS): 6%, Myopathy associated with connective tissue disease: 19%, Associated with statins: 4, 4%, Polimyositis: 10%. Association with neoplasia was observed in 15%. Treatments: Corticoids pulses 21%, corticoids 97% (mean starting dose 45 mg meprednisone), methotrexate 77%, hydroxychloroquine 36%, azathioprine 30%, cyclophosphamide 16%, intravenous immunoglobulin 15%, biological 10% and cyclosporine 3%. Mortality was 22.5% (20/89 patients), CI95 (14.3–32.5). Mean time from diagnosis to the event was 18 months. The primary cause of death was sepsis 14/20 (70%). <h3>Conclusions</h3> Mortality of patients with inflammatory myopathies was 22%, and the primary cause was infectious. In the analysis of multiple variables, male sex, presence of neoplasms and serious infectious complications were significantly factors associated with mortality. <h3>References</h3> J Clin Rheumatol 2016; 22: 51–56. Med Clin 1999; 112:521–6. <h3>Disclosure of Interest</h3> None declared
Characteristics of PD-L1, PD-1 expressions and CD8+ tumor infiltrating lymphocyte in EBV-associated nasopharyngeal carcinoma.
Authors: Komkrit - Mahaprom, Noppadol Larbcharoensub, Ekaphop Sirachainan, Chuleeporn Jiarpinitnun, Narumol Trachu, Juvady Leopairut, Patcharee Karnsombut, Nattha Tubthong, Duangjai Pangpunyakulchai, Nuttapong Ngamphaiboon
Journal: Journal of Clinical Oncology (2015)

6070 Background: Early phase clinical studies showed promising activities of anti-PD1/PD-L1 antibody in squamous cell carcinoma of head and neck (SCCHN). PD-L1 expression is a potential biomarker of these drugs. Tumor Infiltrating Lymphocyte (TIL) was a prognostic marker of HPV+ SCCHN and potentially associated with response of immunomodulatory drugs. Most clinical trials of anti-PD1/PD-L1 often excluded nasopharyngeal carcinoma (NPC). We evaluated characteristics of PD-L1 expression and CD8+ TIL for a future development of anti-PD1/PD-L1 antibody in NPC. Methods: NPC patients were identified through the Ramathibodi Cancer Registry database between 1/2007 and 12/2012. PD-L1 and PD-1 expressions were characterized by immunohistochemistry (IHC) from formalin-fixed paraffin-embedded tumor samples. PD-L1 expression was defined by using a cut-off of ≥1% (≥1-9%=1+, 10-49%=2+, ≥50%=3+). Mean number of CD8+TILs following the analysis of 2-4 images was assessed quantitatively by 2 individual pathologists blinded to outcomes. Tumor EBV status was analyzed by using EBV encoded RNA (EBER) in situ hybridization. Results: 119 NPC samples were analyzed. Overall, PD-L1 expression was positive in 72% (13% IHC 3+). PD1+ was observed in 11% of patients. Most patients had EBER+ tumors (96%). Characteristics were summarized in the table. PD-L1+ was highly observed in male (p=0.02). Mean CD8+ TIL count was significantly deceased with stage at diagnosis (p=0.02). There was no significant correlation between PD-L1 and CD8+ TILs observed. Conclusions: More than 70% of EBV+ NPC expressed PD-L1. These results support future development of anti-PD1/PD-L1 antibody in NPC. Characteristics PD-L1 (%) P-value Mean CD8+ TIL count (±SD) P-value - + Median Age (range) <65 years ≥65 years 48 (24-69) 28(93) 2(7) 53.5 (17-81) 68(85) 12(15) 0.86 0.34 52 (17-81) 60±35 57±30 n/a 0.74 Male Female 15(50) 15(50) 59(74) 21(26) 0.02 62±34 55±34 0.35 Smoking Never Yes 15(63) 9(37) 29(52) 27(48) 0.38 54±30 59±34 0.45 EBV+ EBV- 32(97) 1(3) 82(95) 4(5) 1.00 59±34 47±19 0.44 PD1+ PD1- 3(9) 30(91) 10(12) 76(88) 1.00 71±47 57±31 0.14 Stage 1-2 3-4 5(18) 22(82) 12(15) 67(85) 0.68 77±40 56±31 0.02 Median OS (months) 44.2 54.0 0.76 n/a
AB0520 The role of leptin in sjogren's disease
Authors: M Erdoğan, ME Tezcan, K Başak
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Sjogren9s disease (SD) is a multisystemic disease mostly manifest with sicca symptoms. Lympocytic infiltration of the glandular and extra glanduler organs is the dominant pathologic feature of the disease. Multiple stimulators were accused in the pathogenesis of SD. Leptin, an endogenous peptide, involves in various metabolic processes as well as influence immune system (1). Increased serum leptin level is observed in patients with autoimmune diseases such as SD, systemic lupus erythematosus and rheumatoid arthritis when compared to healthy controls (2). <h3>Objectives</h3> Even if serum leptin level increases in the patient with SD, there is no data about its effect on exocrine glands. We aimed to compare density of leptin in the salivary gland of SD patients with control group. Furthermore we evaluted the relation between intensity of lympocytic infiltration and density of leptin in the salivary glands of SD patients <h3>Methods</h3> We applied leptin immunostain to minor salivary glands samples of 24 SD patientss,who were fullfilled American College of Rheumatology Sjögren9s Disease Classification Criteria (ACR-SDCC) and 19 patients who undergo minor salivary gland biopsy due to clinically on suspicion of SD but not fullfilling the ACR-SDCC and had no lymphocytic focus on biopsy. Herein,leptin density in acinar and ductal structures of the salivary glands were evaluated in both groups.Moreover, minor salivary gland samples of SD patients were also assessed for relationship between focus score, disease progression (evaluated with SSDAI) and leptin immunostaining. <h3>Results</h3> Demographic features of both group were similar. Furhermore, there were no difference in leptin staining features of both group.Additionally, we found that higher focus score (&gt;2) was associated with more diffuse leptin staining and higher SSDAI scores related with diffuse acinar staining. <h3>Conclusions</h3> Different leptin staining features in higher focus score and higher disease activity might indicate the role of leptin especially in more significant disease. Leptin may locally stimulate chemotaxis and activate infiltration of glands with inflammatory cells. We suggested further studies aimed to understand autocrine effect of leptin and evalute its role in SD pathogenesis <h3>References</h3> Stofkova, A. Leptin and adiponectin: from energy and metabolic dysbalance to inflammation and autoimmunity. Endocrine regulations, 2009, 43.4: 157–168. Vadacca, Marta, et al. Leptin in immuno-rheumatological diseases. Cellular &amp; molecular immunology, 2011, 8.3: 203–212. <h3>Disclosure of Interest</h3> None declared
Complications of chronic kidney disease: current state, knowledge gaps, and strategy for action
Authors: Aminu K. Bello, Mona Alrukhaimi, Gloria E. Ashuntantang, Shakti Basnet, Ricardo C. Rotter, Walter G. Douthat, Rumeyza Kazancioglu, Anna Köttgen, Masaomi Nangaku, Neil R. Powe, Sarah L. White, David C. Wheeler, Orson Moe
Journal: Kidney International Supplements (2017)
AB0912 Assesment of clinical and radiological prognostic variables in patients with spondylodiscitis
Authors: JJ Fragio Gil, R Mazarío Gonzalez, M Tasias Pitarch, E Muñoz Calabuig, J Ivorra Cortes, CM Feced Olmos, FM Ortiz-Sanjuan, E Sánchez Labrador, K Arévalo Ruales, E Grau Garcia, I Chalmeta Verdejo, L Gonzalez Puig, I Martínez Cordellat, R Negueroles Albuixech, C Alcañiz Escandell, JE Oller Rodriguez, E Vicens Bernabeu, C Nájera Herranz, I Cánovas Olmos, D Marín Hervás, M Salavert Lleti, JA Román Ivorra
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Spondylodiscitis is an infectious disease of the intervertebral space, often caused by hematological spreading from a distance septic focus, especially Endocarditis. Because of its low incidence combined with an ambiguous symptoms, delay diagnosis and treatment of this condition, raising probability of an undesirable outcome. <h3>Objectives</h3> To identify poor prognosis variables in patients with Spondylodiscitis <h3>Methods</h3> Observational retrospective study with non-quirurgic spondylodiscitis patients from 2010 to 2016 was performed. Demographic information, clinical history, laboratory test and radiological data were compiled from the clinical history management software. Statistical analysis was performed with the software R (version 3.3.2). <h3>Results</h3> We included 55 patients, with a mean age of 63.47 (16.11) years old. Males predominated (69%). The average time with axial pain was 64.44 (80.63) days. Mean length of hospital stay was 64.44 (80.63) days and readmission rate was 32.7%. 20% of patients required further surgical procedures. Most of patients showed high CRP levels at their admission, with an average value of 112.97 (83.64) mg/L. Underlying endocarditis proportion was 16.4% and in this patients hospital stay was significative higher; nevertheless, it was not correlated with worse prognosis. 50% of patients showed vertebral destruction on MRI; 14.8% cord compression and 20.4% of patients developed neurological complications (7 of them paraparesis). Furthermore, vertebral destruction was statistically correlated with epidural abscess (P=0.026). Isolation and microbiological identification in blood cultures was possible in 83.6% of patients. Most frequent bacteria was Gram positive (50.09%), then Gram negative (18.2%), mycobacteria (10,9%) and fungi (3.6%). <h3>Conclusions</h3> Delay in diagnosis is an important issue in Spondylodiscitis patients. Higher complications rates are mainly in relation to greater vertebral destruction. Underlying infectious endocarditis was described in a small proportion of patients in contrast to other studies. Presence of epidural abscess was also correlated with vertebral destruction, for this reason, patients with this finding should be more carefully follow-up. <h3>Disclosure of Interest</h3> None declared
Liver disease mortality varies widely across England
Authors: Anne Gulland
Journal: BMJ (2017)

Rates of death from liver disease vary widely across England, with people in the area with the highest mortality nearly eight times as likely to die prematurely than those in the area with the lowest.

Data from Public Health England looking at variation in health outcomes across the country show that premature mortality associated with liver disease—deaths before the age of 75—ranged from 3.9 cases per 100 000 head of the population in the South Norfolk Clinical Commissioning Group area to 30.1 per …
THU0354 Disease worsening and safety in patients switching from originator infliximab to biosimilar infliximab (CT-P13) in the randomized nor-switch-study: explorative analysis in SPA patients
Authors: GL Goll, IC Olsen, N Bolstad, KK Jørgensen, M Lorentzen, C Mørk, J Jahnsen, EA Haavardsholm, TK Kvien
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> The NOR-SWITCH study is a 52-week randomized, double-blind, non-inferiority, phase IV switch trial in patients with Crohn9s disease (CD), ulcerative colitis (UC), spondyloarthritis (SpA), rheumatoid arthritis (RA), psoriatic arthritis (PsA) and plaque psoriasis (Ps) on stable treatment with originator infliximab (Remicade®, INX), funded by the Norwegian government. Previously, primary analyses of the pooled indications have been published<sup>1</sup>. <h3>Objectives</h3> To investigate efficacy, safety and immunogenicity in SpA patients treated with continuous INX vs patients switched to CT-P13 (biosimilar infliximab, Remsima®) in the NOR-SWITCH study (explorative analyses). <h3>Methods</h3> Patients were randomized 1:1 to continued INX or switch to CT-P13. Serum drug levels were analyzed by automated in-house assay. The primary endpoint was disease worsening according to disease-specific composite measures and/or consensus between investigator/patient. Exploratory subgroup analyses examined disease worsening and safety in SpA. The primary endpoint was analysed by logistic regression, adjusted for diagnosis and disease duration. <h3>Results</h3> Demographics, occurrence of disease worsening, change in disease measures and treatment-emergent adverse events (TEAE) were similar (Table), as were serum drug levels for INX and CT-P13 (Figure). <h3>Conclusions</h3> Explorative analyses in the NOR-SWITCH study showed similar efficacy, drug levels and safety in SpA patients switched to CT-P13 as those on continuous INX. The study was not powered to show non-inferiority within each diagnosis. <h3>References</h3> Jørgensen KK et al. Switching from originator infliximab to biosimilar CT-P13 compared to maintained treatment with originator infliximab (NOR-SWITCH): a 52-week randomised double-blind non-inferiority trial. The Lancet, in press. <h3>Disclosure of Interest</h3> G. Goll Consultant for: AbbVie, Boehringer Ingelheim, Orion Pharma, Novartis, Pfizer, I. Olsen: None declared, N. Bolstad: None declared, K. Jørgensen Consultant for: Celltrion, Intercept, AbbVie, Tillott, M. Lorentzen: None declared, C. Mørk Consultant for: Cellgene, AbbVie, Galderma Nordic, ACOhud, Novartis, LEOPharma, J. Jahnsen Consultant for: Celltrion, Orion Pharma, Pfizer, MSD, AbbVie, Takeda, Napp Pharma, AstroPharma, E. Haavardsholm Consultant for: AbbVie, UCB, Pfizer, MSD, Roche, T. Kvien Consultant for: Biogen, BMS, Boehringer Ingelheim, Celltrion, Eli Lily, Epirus, Hospira, Merck-Serono, Novartis, Orion Pharma, Pfizer, Sandoz, UCB
SAT0710 Renal function contribute to risk of cardiovascular disease in rheumatoid arthritis
Authors: S Hannawi, I Alsalmi
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> The excess mortality associated with rheumatoid arthritis (RA) is due largely to cardiovascular disease. This highest risk is not related primarily to traditional cardiovasculr/atherosclerosis risk factors. The presence of RA indepedently, as well as high inflammation associated with RA has been reported as a cardiovascular risk factors. Also, subclinical decreased kidney function has been identified as an independent risk factor for CV events in patients with RA. The potential impact of impaired kidney function on atherosclerosis in RA requires more elucidation. <h3>Objectives</h3> To assess the role of renal parameters, alongside with inflammation and traditional cardiovascular risk factors in predicting cardiovascular disease; as manifested by carotid intima media thickness (cIMT), among RA population. <h3>Methods</h3> cIMT measurement was carried out in 68 RA patients, and correlated with renal function parameters with adjustment for traditional CV risk factors and RA associated inflammation. Glomerular filtration rate (GFR) was estimated with the abbreviated Modification of Diet in Renal Disease formula. Linear regression determined the association between renal parameters and the thickness of cIMT. <h3>Results</h3> Carotid intima media thickness was positively associated with 1-demographic characteristics of the participants such as age of the participants (p&lt;0.001), and age at RA sumptoms onset (p=0.001). 2-traditional cardiovascular risk factors such as systolic blood pressure (p&lt;0.001), diastolic blood pressure (p=0.016), triglycerid level (p=0.016), and low densilty lipoprotein (LDL) (p=0.001). 3-inflammatory markers such as erythrocytes sedimentation rate (ESR) (p=0.020) and c-reactive protein (CRP) (0.020), and 4-renal function parameters such as uric acid level (p=0.006), urine microalbumin level (p=0.030). cIMT negativlely associated with high density lipoprotein (HDL) (p=0.037), 24 hours urine creatinine level (p=0.020) and glomerular filtration rate (p=0.008). <h3>Conclusions</h3> Subclinical renal function in conjunction with tarditional and non-traditional cardiovascular risk factors work synergistically to accelerate atheroscrlerosis in RA population. <h3>References</h3> Maradit-Kremer H, Crowson, Nicola PJ, Ballman KV, Roger VL, Jacobsen, Gabriel SE. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum, 2005;52:402–411. Roman MJ, Moeller E, Davis A, Paget SA, Crow MK, Lockshin MD, Sammaritano L. Preclinical carotid atherosclerosis in patients with rheumatoid arthritis: prevalence and associated factors. Ann Intern Med, 2006; 144:249–256. van Sijl AM, van den Oever IA, Peters MJ, et al. Subclinical renal dysfunction is independently associated with cardiovascular events in rheumatoid arthritis: the CARRE Study. AnnRheum Dis. 2012;71(3):341–344. <h3>Disclosure of Interest</h3> None declared
Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk Neuroblastoma
Authors: Kristopher R. Bosse, Pichai Raman, Zhongyu Zhu, Maria Lane, Daniel Martinez, Sabine Heitzeneder, Komal S. Rathi, Nathan M. Kendsersky, Michael Randall, Laura Donovan, Sorana Morrissy, Robyn T. Sussman, Doncho V. Zhelev, Yang Feng, Yanping Wang, Jennifer Hwang, Gonzalo Lopez, Jo Lynne Harenza, Jun S. Wei, Bruce Pawel, Tricia Bhatti, Mariarita Santi, Arupa Ganguly, Javed Khan, Marco A. Marra, Michael D. Taylor, Dimiter S. Dimitrov, Crystal L. Mackall, John M. Maris
Journal: Cancer Cell (2017)
Extensive transcriptomic and epigenomic remodelling occurs during Arabidopsis thaliana germination
Authors: Reena Narsai, Quentin Gouil, David Secco, Akanksha Srivastava, Yuliya V. Karpievitch, Lim Chee Liew, Ryan Lister, Mathew G. Lewsey, James Whelan
Journal: Genome biology (2017)

Seed germination involves progression from complete metabolic dormancy to a highly active, growing seedling. Many factors regulate germination and these interact extensively, forming a complex network of inputs that control the seed-to-seedling transition. Our understanding of the direct regulation of gene expression and the dynamic changes in the epigenome and small RNAs during germination is limited. The interactions between genome, transcriptome and epigenome must be revealed in order to identify the regulatory mechanisms that control seed germination. We present an integrated analysis of high-resolution RNA sequencing, small RNA sequencing and MethylC sequencing over ten developmental time points in Arabidopsis thaliana seeds, finding extensive transcriptomic and epigenomic transformations associated with seed germination. We identify previously unannotated loci from which messenger RNAs are expressed transiently during germination and find widespread alternative splicing and divergent isoform abundance of genes involved in RNA processing and splicing. We generate the first dynamic transcription factor network model of germination, identifying known and novel regulatory factors. Expression of both microRNA and short interfering RNA loci changes significantly during germination, particularly between the seed and the post-germinative seedling. These are associated with changes in gene expression and large-scale demethylation observed towards the end of germination, as the epigenome transitions from an embryo-like to a vegetative seedling state. This study reveals the complex dynamics and interactions of the transcriptome and epigenome during seed germination, including the extensive remodelling of the seed DNA methylome from an embryo-like to vegetative-like state during the seed-to-seedling transition. Data are available for exploration in a user-friendly browser at https://jbrowse.latrobe.edu.au/germination_epigenome .
Erratum to: The impact of disability in survivors of critical illness
Authors: Carol L. Hodgson, Andrew A. Udy, Michael Bailey, Jonathan Barrett, Rinaldo Bellomo, Tracey Bucknall, Belinda J. Gabbe, Alisa M. Higgins, Theodore J. Iwashyna, Julian Hunt-Smith, Lynne J. Murray, Paul S. Myles, Jennie Ponsford, David Pilcher, Craig Walker, Meredith Young, D. J. Cooper
Journal: Intensive Care Medicine (2017)